ERBB2 and breast cancer: However, no significant differences in uptake of either 18F-Alfatide II or 68Ga-BBN-RGD were observed between HER2(+) and HER2(−) subtypes in either patients with suspected breast cancer on screening mammography or patients who underwent breast cancer radical mastectomy (p = 0.6589) (88, 116).